BofA/Merrill Lynch Downgrades AstraZeneca (AZN) to Underperform
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Price: $70.85 +1.03%
Rating Summary:
17 Buy, 8 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
17 Buy, 8 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
BofA/Merrill Lynch downgraded AstraZeneca (NYSE: AZN) from Neutral to Underperform.
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $46.79 yesterday.
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $46.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
- Loop Capital Downgrades Matterport, Inc (MTTR) to Hold
- JPMorgan Downgrades Five Below (FIVE) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
